- Conditions
- Hematologic Diseases, Anemia, Sickle Cell, Beta-Thalassemia, Hematopoietic Stem Cell Transplantation
- Interventions
- Sangstat, Cyclophosphamide, Busulfan, Mycophenolate Mofetil, Cyclosporine, Cord Blood Transplantation
- Drug · Procedure
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 3 Years to 14 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2006
- U.S. locations
- 14
- States / cities
- Oakland, California • Washington D.C., District of Columbia • Jacksonville, Florida + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 2,059
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Sickle Cell Disease
- Interventions
- Sapropterin Dihydrochloride
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 15 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 12
- States / cities
- Washington D.C., District of Columbia • Augusta, Georgia • Savannah, Georgia + 9 more
- Conditions
- Sickle Cell Anemia, Sickle ß0-Thalassemia
- Interventions
- L-glutamine, Placebo
- Drug
- Lead sponsor
- Emmaus Medical, Inc.
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 31
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Inglewood, California + 23 more
- Conditions
- Sickle Cell Anemia
- Interventions
- ACZ885, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 8 Years to 20 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Augusta, Georgia • Greenville, North Carolina
- Conditions
- Sickle Cell Disease, Transfusion-dependent Beta-Thalassemia, Hemoglobinopathies
- Interventions
- Safety and efficacy assessments
- Other
- Lead sponsor
- Editas Medicine, Inc.
- Industry
- Eligibility
- 12 Years to 50 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2040
- U.S. locations
- 16
- States / cities
- Oakland, California • Aurora, Colorado • New Haven, Connecticut + 12 more
- Conditions
- Agglutinin Disease, Cold
- Interventions
- BIVV009
- Drug
- Lead sponsor
- Bioverativ, a Sanofi company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 13
- States / cities
- Tucson, Arizona • Los Angeles, California • Whittier, California + 9 more
- Conditions
- Anaemia
- Interventions
- Daprodustat, Darbepoetin alfa, Placebo, Iron Therapy
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 3,872 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 161
- States / cities
- Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 128 more
- Conditions
- Sickle Cell Disease
- Interventions
- massage, relaxation
- Procedure · Behavioral
- Lead sponsor
- National Center for Complementary and Integrative Health (NCCIH)
- NIH
- Eligibility
- 15 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Tampa, Florida
- Conditions
- Hookworm Infection, Hookworm Disease
- Interventions
- Na-GST-1/Alhydrogel®, CpG 10104
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Sickle Cell Disease, Sickle Cell Anemia, Stroke, Ischemic, Silent Stroke, Silent Cerebral Infarct, Stroke
- Interventions
- Hydroxyurea therapy per standard care
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 16 Years to 26 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Congenital Hemolytic Anemia, Sickle Cell Disease
- Interventions
- Peripheral blood hematopoietic progenitor cell (PBPC) transplant, Alemtuzumab, Peripheral blood hematopoietic progenitor cell Apheresis, Sirolimus
- Procedure · Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 2 Years to 80 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Essential Thrombocythemia, Polycythemia Vera, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia
- Interventions
- therapeutic allogeneic lymphocytes, aldesleukin, peripheral blood stem cell transplantation, allogeneic bone marrow transplantation, laboratory biomarker analysis, gene expression analysis, immunologic technique, flow cytometry, polymerase chain reaction, cytogenetic analysis, staining method
- Biological · Procedure · Other + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2013
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Anemia
- Interventions
- Ferric Carboxymaltose, Standard Medical Care (SMC)
- Drug
- Lead sponsor
- American Regent, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 513 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Norristown, Pennsylvania
- Conditions
- Anemia, Sickle Cell
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 3,640 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 13
- States / cities
- Oakland, California • San Francisco, California • Boston, Massachusetts + 6 more
- Conditions
- Sickle Cell Disease
- Interventions
- WEB-MAP Educational Control Group, WEB-MAP CBT
- Behavioral
- Lead sponsor
- Connecticut Children's Medical Center
- Other
- Eligibility
- 11 Years to 18 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Hartford, Connecticut
- Conditions
- Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- amifostine trihydrate
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 74
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 67 more
- Conditions
- Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease, Vaso-occlusive Crisis
- Interventions
- Inclacumab, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 22
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Orange, California + 7 more
- Conditions
- Sickle Cell Disease
- Interventions
- Linkage Coordinator
- Behavioral
- Lead sponsor
- RTI International
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Oakland, California + 6 more
- Conditions
- Anemia of Chronic Kidney Disease
- Interventions
- ferric citrate, Placebo
- Drug
- Lead sponsor
- Keryx Biopharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Glendale, California + 29 more
- Conditions
- Sickle Cell Anemia
- Interventions
- Hydroxyurea, Placebo
- Drug · Other
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 6 Months to 12 Months
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Breast Cancer, Neoplasm Metastasis
- Interventions
- Standard supportive care (packed RBC transfusion), epoetin alfa + packed RBC transfusion
- Other · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 99 Years · Female only
- Enrollment
- 2,098 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2017
- U.S. locations
- 14
- States / cities
- Anaheim, California • Gainesville, Florida • Miami, Florida + 11 more
- Conditions
- Sickle Cell Disease
- Interventions
- Mometasone Furoate, Placebo
- Drug
- Lead sponsor
- Jeffrey Glassberg
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Anaemia
- Interventions
- Daprodustat, rhEPO, Ferrous sulfate containing the stable iron isotope (57Fe), Ferrous sulfate containing the stable iron isotope (58Fe)
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 3
- States / cities
- Fort Worth, Texas • Lufkin, Texas • San Antonio, Texas
- Conditions
- Sickle Cell Disease
- Interventions
- Gabapentin, Placebo
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 1 Year to 20 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee